The study investigated possible mechanisms by which second-generation taxanes, established as significantly more effective than paclitaxel in vitro, suppress a rat lymphoma model in vivo. The studied mechanisms included taxane pharmacokinetics, expression of genes dominating their metabolism (Cyp3a1/2) and transport (Abcb1) and genes controlling tumour angiogenesis (growth factors and receptors). SB-T-1214, SB-T-12854 and IDN5109 suppressed rat lymphoma more effectively than paclitaxel, SB-T-12851, SB-T-12852, SB-T-12853 or IDN5390 as well as P388D1 leukaemia cells in vitro. The greater anti-lymphoma effects of SB-T-1214 in rats corresponded to a higher bioavailability than with SB-T-12854, and lower systemic toxicity of SB-T-1214 for rats reflected its lower cytotoxicity for P388D1 cells in vitro. Suppression of Abcb1 and CYP3a1 expression by SB-T-1214 and IDN5109 could partly explain their anti-lymphoma effects, but not that of SB-T-12854. Growth factors genes Egf, Fgf, Pdgf, and Vegf associated with tumour angiogenesis had significantly lower expression following treatment with anti-lymphoma effective IDN5109 and their receptors were unaffected, whereas inefficient IDN5390 increased expression of the most important Vegf. The effective SB-T-12854 inhibited Egf, Egfr, Fgfr and Pdgfr expression, while the ineffective SB-T-12851, SB-T-12852 and SB-T-12853 inhibited only Egf or Egfr expression. Vegfr expression was inhibited significantly by SB-T-12851 and SB-T-12854, but effect of SB-T-12851 was compromised by induced Vegf expression. The very effective SB-T-1214 decreased the expression of Vegf, Egf and all receptors most prominently indicating the possible supporting role of these genes in anti-lymphoma effects. In conclusion, SB-T-1214, SB-T-12854 and IDN5109 are good candidates for further study.

Institute of Biology and Medical Genetics 1st Faculty of Medicine and General Teaching Hospital Charles University 128 00 Prague Czech Republic

Zobrazit více v PubMed

Endothelium. 2008 Jan-Feb;15(1):9-15 PubMed

Invest New Drugs. 2010 Dec;28 Suppl 1:S58-78 PubMed

Folia Biol (Praha). 2002;48(6):213-26 PubMed

Eur J Pharm Sci. 2006 Dec;29(5):442-50 PubMed

Cancer Res. 2005 Mar 15;65(6):2397-405 PubMed

Bull Cancer. 2010 Apr;97(4):E23-32 PubMed

Clin Cancer Res. 2002 Apr;8(4):1182-8 PubMed

Clin Pharmacol Ther. 2003 Oct;74(4):364-71 PubMed

Toxicol Lett. 2010 Jul 1;196(2):74-9 PubMed

Exp Cell Res. 2006 Mar 10;312(5):549-60 PubMed

Xenobiotica. 2006 Sep;36(9):772-92 PubMed

Cancer Lett. 2005 Apr 18;221(1):105-18 PubMed

Arch Toxicol. 2000 Oct;74(8):437-46 PubMed

Invest New Drugs. 2011 Jun;29(3):411-23 PubMed

Pharmacogenet Genomics. 2008 Mar;18(3):263-73 PubMed

Trials. 2010 May 25;11:62 PubMed

Clin Cancer Res. 2001 Dec;7(12):4156-63 PubMed

J Oncol Pharm Pract. 2011 Sep;17(3):179-85 PubMed

Cancer Chemother Pharmacol. 1989;24(3):148-54 PubMed

Anticancer Res. 2000 Mar-Apr;20(2A):1041-7 PubMed

J Med Chem. 1997 Jan 31;40(3):267-78 PubMed

Acc Chem Res. 2008 Jan;41(1):108-19 PubMed

Anticancer Res. 2005 Nov-Dec;25(6B):4215-24 PubMed

J Chem Inf Model. 2009 Feb;49(2):424-36 PubMed

Oncol Rep. 2006 Feb;15(2):329-34 PubMed

ChemMedChem. 2007 Jul;2(7):920-42 PubMed

Stem Cells. 2005 Oct;23(9):1417-22 PubMed

J Med Chem. 1996 Sep 27;39(20):3889-96 PubMed

Cell Mol Life Sci. 2006 Mar;63(5):601-15 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2005 Jul;372(1):95-105 PubMed

Clin Cancer Res. 2002 Aug;8(8):2647-54 PubMed

Anticancer Res. 2009 Aug;29(8):2951-60 PubMed

J Natl Cancer Inst. 2001 Aug 15;93(16):1234-45 PubMed

J Med Chem. 2008 Jun 12;51(11):3203-21 PubMed

Nature. 2000 Sep 14;407(6801):249-57 PubMed

Crit Rev Oncol Hematol. 2007 May;62(2):105-18 PubMed

Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma

Anticancer regimens containing third generation taxanes SB-T-121605 and SB-T-121606 are highly effective in resistant ovarian carcinoma model

Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216